SARS-CoV-2 and the immune system: a battle of titans
DOI:
https://doi.org/10.24265/horizmed.2020.v20n2.12Keywords:
Coronavirus infections, Immune system, Diagnosis, ImmunotherapyAbstract
Humankind is currently facing a challenge that distinguishes no borders, ideologies, socioeconomic systems, ethnic groups, religions or cultures. It is a war that unites us as a biological species, in which the main weapons come from research aimed at improving health systems. In this war, governments and international health organizations define the strategy; and health systems and law enforcement agencies, together with citizens’ support, carry out actions and fight the battles. However, the most important battle is fought inside each of us. Just like Perseus fought against Hades in a battle of titans to prevent the Earth from turning into hell, the immune system activates a powerful machinery in which molecules and cells of the innate and acquired immune system jointly act to defeat SARS-Cov-2: a machinery that follows a script written by evolution, and that will leave in our immune system a memory that will strengthen us as a species to face future Hades. This work summarizes valuable information published in recent months regarding the interaction between SARS-Cov-2 and the immune system. It also includes aspects related to the detection of the immune response as a tool for the diagnosis of this infection, as well as the manipulation of the immune system to prevent or treat the disease.
Downloads
References
GenBank. Severe acute respiratory syndrome coronavirus 2 isolate Wuhan-Hu-1, complete genome. Disponible en: https://www.ncbi.nlm.nih.gov/nuccore/MN908947.3
World Health Organization. Novel Coronavirus (2019-nCoV) situation reports. Disponible en: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
Cyranoski D. Mystery deepens over animal source of coronavirus. Nature. 2020; 579(7797): 18-9.
Cui J, Li F, Shi Z-L. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019; 17(3): 181-92.
Paules CI, Marston HD, Fauci AS. Coronavirus infections-more than just the common cold. JAMA. 2020; 323(8): 707-8.
Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol. 2020; 38(1): 1-9.
Kai-Wang K, Tsang O, Chik-Yan C, Chan KH, Wu TC, Chan JM, et al. Consistent detection of 2019 novel coronavirus in saliva. Clin Infect Dis. 2020.
Yeo C, Kaushal S, Yeo D. Enteric involvement of coronaviruses: is faecal-oral transmission of SARS-CoV-2 possible?. Lancet Gastroenterol Hepatol. 2020; 5(4): 335-7.
Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet. 2020; 395(10226): 809-15.
Walls AC, Park Y, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020.
Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, et.al. Coronavirus infections and immune responses. J Med Virol. 2020; 92(4): 424-32.
Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol. 2014; 14(1): 36-49.
Le Bon A, Etchart N, Rossmann C, Ashton M, Hou S, Gewert D, et al. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat Immunol. 2003; 4(10): 1009-15.
Chen J, Lau YF, Lamirande EW, Paddock CD, Bartlett JH, Zaki SR, et al. Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4+ T cells are important in control of SARS-CoV infection. J Med Virol. 2010; 84(3): 1289-1301.
Ababneh M, Alrwashdeh M, Khalifeh M. Recombinant adenoviral vaccine encoding the spike 1 subunit of the Middle East Respiratory Syndrome Coronavirus elicits strong humoral and cellular immune responses in mice. Vet World. 2019; 12(10): 1554-62.
Liu W, Fontanet A, Zhang PH, Zhan L, Xin ZT, Baril L, et al. Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome. J Infect Dis. 2006; 193(6): 792-5.
Lessler J, Reich NG, Brookmeyer R, Perl TM, Nelson KE, Cummings DA. Incubation periods of acute respiratory viral infections: a systematic review. Lancet Infect Dis. 2009; 9(5): 291-300.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395: 497-506.
Mahallawi WH, Khabour OF, Zhang Q, Makhdoum HM, Suliman BA. MERS-CoV infection in humans is associated with a proinflammatory Th1 and Th17 cytokine profile. Cytokine. 2018; 104: 8-13.
Wong CK, Lam CW, Wu AK, Ip WK, Lee NL, Chan IH, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol. 2004; 136(1): 95-103.
Yajing F, Cheng Y, Wu Y. Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools. Virol Sin. 2020.
Kikkert M. Innate immune evasion by human Respiratory RNA Viruses. J Innate Immun. 2020; 12(1): 4-20.
Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017; 39(5): 529-39.
Shokri S, Mahmoudvand S, Taherkhani R, Farshadpour F. Modulation of the immune response by Middle East respiratory syndrome coronavirus. J Cell Physiol. 2019; 234(3): 2143-51.
Zhang L, Zhang F, Yu W, He T, Yu J, Yi CE, et. al. Antibody responses against SARS coronavirus are correlated with disease outcome of infected individuals. J Med Virol. 2006; 78: 1-8.
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020.
Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020.
Lippi G, Simundica AM, Plebania M. Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19). Clin Chem Lab Med. 2020.
Deng Y, Lan J, Bao L, Huang B, Ye F, Chen Y, et al. Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of middle east respiratory syndrome coronavirus. Emerg Microbes Infect. 2018; 7(1): 60.
Modjarrad K, Roberts CC, Mills KT, Castellano AR, Paolino K, Muthumani K, et al. Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial. Lancet Infect Dis. 2019; 19(9): 1013-22.
Lin JT, Zhang JS, Su N, Xu JG, Wang N, Chen JT, et al. Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine. Antivir Ther. 2007; 12(7): 1107-13.
Lanese N, Writer S. First coronavirus vaccine trial in the US is recruiting volunteers. Live Science. 2020. Disponible en: https:// www.livescience.com/us-coronavirus-vaccine-trial-recruiting. html
Ying T, Du L, Ju TW, et al. Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. J Virol. 2014; 88(14): 7796-7805.
Tseng C-TK, Huang C, Newman P, Wang N, Narayanan K, Watts DM, et al. Severe acute respiratory syndrome coronavirus infection of mice transgenic for the human Angiotensin-converting enzyme 2 virus receptor. J Virol. 2007; 81(3): 1162-73.
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Horizonte Médico (Lima)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Horizonte Médico (Lima) (Horiz. Med.) journal’s research outputs are published free of charge and are freely available to download under the open access model, aimed at disseminating works and experiences developed in biomedical and public health areas, both nationally and internationally, and promoting research in the different fields of human medicine. All manuscripts accepted and published in the journal are distributed free of charge under the terms of a Creative Commons license – Attribution 4.0 International (CC BY 4.0).
